Literature DB >> 28752369

Ranibizumab versus dexamethasone implant for central retinal vein occlusion: special remarks of the RANIDEX study.

I Chatziralli1, G Theodossiadis2, S A Kabanarou3, P Theodossiadis2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28752369     DOI： 10.1007/s00417-017-3750-6

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  4 in total

1.  Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the RANIDEX study.

Authors:  Irini Chatziralli; George Theodossiadis; Stamatina A Kabanarou; Efstratios Parikakis; Tina Xirou; Panagiotis Mitropoulos; Panagiotis Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-06-15       Impact factor: 3.117

2.  Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.

Authors:  Julia A Haller; Francesco Bandello; Rubens Belfort; Mark S Blumenkranz; Mark Gillies; Jeffrey Heier; Anat Loewenstein; Young Hee Yoon; Jenny Jiao; Xiao-Yan Li; Scott M Whitcup; Joanne Li
Journal:  Ophthalmology       Date:  2011-07-20       Impact factor: 12.079

3.  RANIBIZUMAB FOR RETINAL VEIN OCCLUSION: Predictive Factors and Long-Term Outcomes in Real-Life Data.

Authors:  Irini Chatziralli; George Theodossiadis; Alexandros Chatzirallis; Efstratios Parikakis; Panagiotis Mitropoulos; Panagiotis Theodossiadis
Journal:  Retina       Date:  2018-03       Impact factor: 4.256

4.  Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.

Authors:  Peter A Campochiaro; David M Brown; Carl C Awh; S Young Lee; Sarah Gray; Namrata Saroj; Wendy Yee Murahashi; Roman G Rubio
Journal:  Ophthalmology       Date:  2011-06-29       Impact factor: 12.079
  4 in total
  1 in total

Review 1.  [Retinal vein occlusion : Intravitreal pharmacotherapies and treatment strategies for the management of macular edema].

Authors:  Lars-Olof Hattenbach; Argyrios Chronopoulos; Nicolas Feltgen
Journal:  Ophthalmologie       Date:  2022-10-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.